Ei­sai prices Alzheimer's drug at $26,500, be­low part­ner Bio­gen's Aduhelm

Ei­sai and Bio­gen will price their new Alzheimer’s treat­ment Leqem­bi at $26,500 per year, US CEO Ivan Che­ung tells End­points News. With out­cries over the …

Endpoints News

Sign up to read this article for free.

Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.